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ABSTRACT
Objective To compare the performance of three placental
growth factor (PlGF)-based tests in predicting delivery
within 14 days from testing in women with suspected
preterm pre-eclampsia before 35weeks’ gestation.
Methods This was a retrospective analysis of samples
collected from three prospective pregnancy cohort stud-
ies. Participants were pregnant women with suspected
preterm pre-eclampsia recruited in tertiary maternity units
in the UK and Ireland. Samples were analyzed simulta-
neously according to the manufacturers’ directions. The
tests compared were the DELFIA Xpress PlGF 1-2-3 test,
the Triage PlGF test and the Elecsys immunoassay sol-
uble fms-like tyrosine kinase-1 (sFlt-1)/PlGF ratio. Areas
under receiver–operating characteristics curves (AUCs)
were compared. Themain outcomemeasure was detection
of a difference of 0.05 in AUC between tests for delivery
within 14 days of testing.
Results Plasma samples from 396women and serum sam-
ples from 244 women were assayed. In predicting delivery
within 14 days secondary to suspected pre-eclampsia prior
to 35weeks’ gestation, no significant differences were
observed in AUCs (P = 0.795), sensitivities (P = 0.249),
positive predictive values (P = 0.765) or negative pre-
dictive values (P = 0.920) between the three tests. The
specificity of the Elecsys sFlt-1/PlGF ratio test was higher
than that of the other two tests (P< 0.001).
Conclusions The tests perform similarly in their pre-
diction of need for delivery within 14 days in women
with suspected pre-eclampsia. The high negative
predictive values support the role of PlGF-based tests
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as ‘rule-out’ tests for pre-eclampsia.  2018 The Authors.
Ultrasound in Obstetrics & Gynecology published by
John Wiley & Sons Ltd on behalf of the International
Society of Ultrasound in Obstetrics and Gynecology.
INTRODUCTION
Placental growth factor (PlGF) is an angiogenic protein
synthesized by syncytiotrophoblasts. A low PlGF con-
centration is considered to be a reflection of placental
dysfunction, and has been shown to correlate strongly
with time to delivery in women with suspected preterm
(< 35weeks’ gestation) pre-eclampsia1,2. Other tests used
for the prediction of time to delivery measure addition-
ally soluble fms-like tyrosine kinase-1 (sFlt-1) and utilize
the ratio of both factors (sFlt-1/PlGF). These tests are
advocated by the UK National Institute for Health and
Care Excellence (NICE) for use in women with suspected
preterm pre-eclampsia, in particular as a ‘rule-out’ tool3.
Several companies manufacture PlGF-based tests that
can be used in clinical practice to assist in ruling
out a diagnosis of pre-eclampsia in women presenting
with suspected preterm pre-eclampsia. These include
the DELFIA Xpress PlGF 1-2-3 test (Perkin Elmer),
Triage PlGF test (Alere International) and the Elecsys
immunoassay sFlt-1/PlGF ratio (Roche Diagnostics). The
Triage PlGF test and the Elecsys immunoassay sFlt-1/PlGF
ratio, used with standard clinical assessment and
subsequent clinical follow-up, are currently recommended
by NICE for this purpose.
Further research has been recommended by NICE
to show the clinical effectiveness of the DELFIA
Xpress PlGF 1-2-3 test before routine adoption in a
health-service setting. It is also unclear whether significant
 2018 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd ORIGINAL PAPER
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
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differences exist between assays using plasma or
serum samples.
The main aim of this study was to compare the
performance of three PlGF-based tests in the prediction
of time to delivery within 14 days from testing in women
with suspected preterm pre-eclampsia prior to 35weeks’
gestation, using derived or recommended thresholds.
Secondary aims included the derivation of a cut-off-value
based prediction model for the DELFIA Xpress PlGF
1-2-3 test and comparison of the use of plasma or serum
samples in the Elecsys immunoassay sFlt-1/PlGF ratio and
DELFIA Xpress PlGF 1-2-3 tests.
METHODS
We conducted a retrospective analysis of samples
collected as part of three prospective pregnancy cohorts
(PEACHES4, PELICAN-11 and PELICAN-25). Women
were eligible for inclusion in this study if they presented
with suspected preterm pre-eclampsia or suspected
fetal growth restriction before 37weeks’ gestation and
when there were at least three sample aliquots available
to allow measurement using each of the three tests
being analyzed: DELFIA Xpress PlGF 1-2-3 test; Triage
PlGF test; and Elecsys immunoassay sFlt-1/PlGF ratio.
Whole aliquots were used for each test, and no sample
had been exposed to a freeze–thaw cycle. Samples
were processed for each platform simultaneously under
similar conditions according to the manufacturers’
directions. When such samples were available, both
serum and plasma were analyzed for the DELFIA
Xpress PlGF 1-2-3 test and Elecsys immunoassay
sFlt-1/PlGF test. All samples available for analysis
within the cohorts were selected and analyzed and all
data presented.
PEACHES cohort
The Pre-Eclampsia And Chronic Hypertension, rEnal
and SLE (PEACHES) study was a prospective mul-
ticenter study investigating biomarkers in pregnancy
hypertension, as described in detail elsewhere4. In brief,
womenwere enrolled prospectively from two London aca-
demic health science centers (Imperial College and King’s
Health Partners) between June 2009 and January 2017.
Demographic information was recorded following writ-
ten informed consent. Ethylenediamine tetraacetic acid
(EDTA) plasma or serum samples were collected from par-
ticipants with suspected pre-eclampsia. Whole blood was
spun at 1400 g for 10min at 4 ◦C and divided into aliquots
of 250µL before being stored in a freezer at −80 ◦C
until use. Maternal and perinatal outcome data were
obtained by case-note review after delivery. Definitions
for study entry and outcomes were based on Interna-
tional Society for the Study of Hypertension in Pregnancy
guidelines6. All data and final diagnoses were entered by
one researcher, confirmed by a second reviewer and, for
complex cases, the diagnosis was adjudicated by a third
senior reviewer, all without access to study (biomarker)
results. Exclusion criteria were maternal age< 18 years
or> 50 years, inability or unwillingness to give informed
consent, known HIV, hepatitis B or C positive or multife-
tal pregnancy. Ethical approval for the PEACHES study
was provided by the National Research Ethics Service
(11/LO/1776).
PELICAN-1 and PELICAN-2 studies
The PELICAN (plasma placental growth factor in the
diagnosis of women with pre-eclampsia requiring delivery
within 14 days) studies were prospective multicenter
observational studies undertaken between January 2011
and February 2012 in seven consultant-led maternity
units in the UK and Ireland (PELICAN-1 study)1 and
between December 2011 and July 2013 in 11 sites in
the UK (PELICAN-2 study)5. Women were eligible for
inclusion if they presented with, or were referred with,
symptoms or signs of suspected pre-eclampsia or with
reduced symphysis–fundus height and were≥ 16 years of
age. For the purposes of this analysis, only samples from
women presenting between 24 and 37weeks’ gestation
with a singleton pregnancy were included. In both studies,
blood (additional to routine blood samples) was drawn
into EDTA and transported to the laboratory within
1 h and plasma was stored at −80 ◦C until analysis.
Pregnancy outcomes of the mother and infant were
obtained from case notes and electronic database review.
Participants were recruited until sufficient numbers
in each pre-specified gestational-age range had been
reached. The PELICAN studies were approved by East
London Research Ethics Committee (ref. 10/H0701/117),
and written informed consent was obtained from all
participants.
PlGF-based tests
The Triage PlGF test is a single-use, fluorescence
immunoassay device, which is used with the Triage
MeterPro point-of-care analyzer. The test has a lower
limit of detection of 9 pg/mL and a measurable range
of 12 to 3000 pg/mL. Using this assay, a PlGF level
of ≥ 100pg/mL is considered test negative (normal),
suggestive of patients without placental dysfunction who
are unlikely to progress to delivery within 14 days from
testing1.
The Elecsys immunoassay sFlt-1/PlGF ratio measures
the level of PlGF relative to sFlt-1 in serum samples
from women with suspected pre-eclampsia. The ratio is
derived by combining the results from two CE-approved
sandwich electrochemiluminescence immunoassays. The
Elecsys sFlt-1 assay has a lower limit of detection of
10 pg/mL (measuring range, 10–85 000 pg/mL) and a
limit of quantitation of 15 pg/mL. The Elecsys PlGF assay
has a lower limit of detection of 3 pg/mL and a measuring
range of 3 to 10 000 pg/mL. The recommended test
cut-off value to rule out pre-eclampsia within 1week is a
ratio of < 387.
 2018 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2019; 53: 62–67.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
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The DELFIA Xpress PlGF 1-2-3 test is a fluoroimmuno-
metric sandwich assay for the quantitative determination
of PlGF in serum samples. The assay has a limit of detec-
tion of 1.9 pg/mL (measuring range, 1.9–4000 pg/mL)
and a limit of quantitation of 3.3 pg/mL. The literature
surrounding appropriate cut-offs for the prediction of
time to delivery in pre-eclampsia is limited, and research
using this test has focused on the first-trimester prediction
of pre-eclampsia8. However, the company suggests that
values below a fixed cut-off of 184 pg/mL may be used
to indicate an increased probability of pre-eclampsia
developing.
Power calculation and statistical analysis
The main aim of this study was to show non-inferiority
between the DELFIA Xpress PlGF 1-2-3 test and each
of the alternative tests, Elecsys immunoassay sFlt-1/PlGF
ratio and Triage PlGF, in the prediction of time to delivery
in women with suspected preterm pre-eclampsia prior
to 35weeks’ gestation, by comparison of the areas under
receiver–operating characteristics curves (AUCs). A pre-
defined analysis plan identified the primary outcome as an
AUC difference of 0.05 between the tests for prediction
of time to delivery within 14 days of testing in women
presenting with suspected preterm pre-eclampsia before
35weeks’ gestation. The pre-defined secondary analysis
included additional analyses of all women < 37weeks,
those presenting between 35 and 36+ 6weeks and stratifi-
cation by final diagnosis of pre-eclampsia. Each subgroup
analysis included the calculation of positive and negative
predictive values (PPV and NPV), sensitivity and speci-
ficity of each test using the currently recommended or
derived threshold (for the DELFIA Xpress PlGF 1-2-3
test). Finally, a comparison between plasma and serum
measurements for the DELFIA Xpress PlGF 1-2-3 test
and the Elecsys immunoassay sFlt-1/PlGF assay was
performed. To allow direct comparison of NPV and PPV
across tests, all NPVs and PPVs were calculated using an
assumed prevalence of 15% for preterm pre-eclampsia
in this population.
A power calculation was performed with the aim of
showing equivalence, defined as a difference of less than
0.05 in the AUC between assays. Based on a prevalence of
pre-eclampsia of 15%, we planned that the study should
have a power of 94.2% to detect or reject a difference
between the predictive power of the tests, as measured by
a difference in AUC of 0.05 or more.
Demographic data are presented as median (interquar-
tile range) or n (%).Normality of distributionwas explored
using a Q-Q plot, and logarithmic transformations were
used where appropriate. t-tests or the Mann–Whitney
U-test, and Fisher’s exact test were used to test differences
between groups. Statistical analysis was performed
using statistical package Stata Version 13 (Stata
Corp., College Station, TX, USA) and SPSS Version 21
(IBM Corp., Armonk, NY, USA).
RESULTS
Three hundred and ninety-six women were enrolled in the
study; plasma samples from 396 and serum samples
from 244 women were assayed. Baseline characteristics
at booking and study enrolment are presented in
Table 1 and maternal outcomes are shown in Table 2.
Overall, 62 (16%) women had a final diagnosis of
preterm pre-eclampsia. DELFIA Xpress PlGF 1-2-3 test
concentrations were examined and a concentration of
< 150pg/mL was determined to give an optimal test
performance, with the same overall proportion of positive
tests (37%) as the triage PlGF test, without regard to
the final diagnosis. This value (150 pg/mL) was used for
comparisons between tests.
No significant differences were observed between the
three tests in the prediction of delivery within 14 days
secondary to suspected pre-eclampsia before 35weeks’
gestation in AUC (P = 0.795), sensitivity (P = 0.249),
PPV (P =0.765) or NPV (P = 0.920) (Table 3). Minor
differences were observed across all tests, both in serum
and plasma samples, with tests having similar AUCs
(ranging from 0.843 to 0.875) and NPVs ranging from
0.951 to 0.972 (n = 198 for serum, n = 305 for EDTA;
Table 3 and Figure S1). At commercially recommended
thresholds, the Elecsys immunoassay sFlt-1/PlGF ratio
had significantly higher specificity than did the DELFIA
Table 1 Maternal characteristics, at booking and enrolment, of
396 women with singleton pregnancy and suspected preterm
pre-eclampsia, according to gestational age at time of presentation
Gestational age (weeks)
< 35+ 0 35+ 0 to 36+6
Variable (n = 327) (n =69)
Age (years) 33.4 (29.5–36.8) 32.2 (27.9–35.6)
Body mass index (kg/m2) 24.5 (21.5–30.5) 22.8 (20.8–26.4)
Nulliparous 155 (47) 34 (49)
Ethnicity
White 151 (46) 39 (57)
Black 89 (27) 8 (12)
Asian 24 (7) 11 (16)
Other 63 (19) 11 (16)
First-trimester
SBP (mmHg)
112 (100–133) 110 (100–117)
First-trimester
DBP (mmHg)
70 (60–90) 68 (60–74)
Smoking status
Currently smoking 14 (4) 6 (9)
Quit smoking 35 (11) 11 (16)
Never smoked 278 (85) 52 (75)
Medical history
Previous pre-eclampsia 32 (10) 5 (7)
Chronic hypertension 109 (33) 5 (7)
SLE/APS 8 (2) 0 (0)
Pregestational
diabetes mellitus
9 (3) 2 (3)
Renal disease 69 (21) 3 (4)
GA at enrolment (weeks) 27.9 (20.0–32.0) 36.0 (35.7–36.5)
Data are presented as median (interquartile range) or n (%). APS,
antiphospholipid syndrome; DBP, highest diastolic blood pressure;
GA, gestational age; SBP, highest systolic blood pressure; SLE,
systemic lupus erythematosus.
 2018 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2019; 53: 62–67.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
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Table 2 Delivery characteristics and outcome of 396 singleton
pregnancies with suspected preterm pre-eclampsia, according to
gestational age at time of presentation
Gestational age (weeks)
<35+ 0 35+0 to 36+ 6
Variable (n =327) (n = 69)
Final diagnosis (exclusive)
Pre-eclampsia 52 (16) 10 (14)
GH 17 (5) 14 (20)
CH only 48 (15) 2 (3)
Normal 127 (39) 32 (46)
Other 77 (24) 10 (14)
Antihypertensive use
None 206 (63) 48 (70)
One drug 64 (20) 13 (19)
Two drugs 44 (13) 5 (7)
Three or more drugs 13 (4) 3 (4)
GA at delivery (weeks) 39 (37.0–40.4) 38.9 (37.5–40.4)
Preterm delivery
< 37weeks
80 (24) 9 (13)
Mode of delivery
Spontaneous vaginal 157 (48) 33 (48)
Assisted vaginal 39 (12) 15 (22)
Cesarean section 128 (39) 21 (30)
Fetal death 1 (0.3) 0 (0)
Neonatal death 3 (0.9) 0 (0)
Birth weight (g) 3053 (2550–3430) 3000 (2660–3350)
SGA
< 10th centile* 27 (8) 2 (3)
< 3rd centile* 9 (3) 0 (0)
Data are presented as n (%) or median (interquartile range).
Outcome data missing in some cases. *Customized birth-weight
centile. CH, chronic hypertension; GA, gestational age; GH,
gestational hypertension; SGA, small-for-gestational age.
Xpress PlGF 1-2-3 test and the Triage PlGF test
(P < 0.001; Table 3).
When comparing the performance of the tests for
all women before 37weeks’ gestation, no significant
differences were observed. However, there was an overall
reduction in the AUCs, with value range dropping from
0.843–0.863 for women presenting before 35weeks to
0.799–0.826 for all women presenting before 37weeks.
Similar changes were observed in the other parameters
(Table S1). Analysis was then repeated but confined
to women sampled between 35 and 36+6weeks’
gestation (n = 46 for serum, n = 91 for EDTA; Table S2).
Overall, the AUCs were lower (ranging from 0.576
to 0.674) but the NPVs remained high, ranging from
0.861 to 0.933.
Analyses were also repeated for low PlGF or high
sFlt-1/PlGF ratio in the prediction of delivery for women
with confirmed pre-eclampsia before 35weeks requiring
delivery within 14 days (Table S3). The AUCs increased
from values ranging between 0.843 and 0.875 (Table 3)
to values between 0.845 and 0.920.
Finally, a comparison of plasma vs serum samples
was performed in the DELFIA Xpress PlGF 1-2-3 and
Elecsys immunoassay sFlt-1/PlGF ratio tests (Table S4).
Small but significant differences were observed in the
DELFIA Xpress PlGF 1-2-3 test, with an AUC of
0.87 (95% CI, 0.77–0.98) for plasma vs an AUC of
0.85 (95%CI, 0.74–0.95) for serum (P = 0.012). No
differences were observed between plasma and serum in
the AUC for Elecsys immunoassay sFlt-1/PlGF ratio test
(P = 0.609).
Table 3 Test performance statistics for low placental growth factor (PlGF) or high soluble fms-like tyrosine kinase-1 (sFlt-1)/PlGF ratio in
prediction of delivery within 14 days secondary to suspected pre-eclampsia in all women who presented before 35weeks’ gestation
DELFIA Xpress PlGF 1-2-3 test Triage PlGF Elecsys sFlt-1/PlGF ratio
Parameter EDTA (n = 305) Serum (n =198) EDTA (n = 305) Serum (n =198) EDTA (n = 305)
Threshold <150pg/mL < 150pg/mL <100pg/mL > 38 > 38
Median (range) PlGF
or sFlt-1/PlGF
319.4
(140.1–662.9)
302.7
(110.2–605.5)
293.0
(99.4–642.0)
4.2
(2.1–11.0)
4.1
(1.9–9.4)
AUC 0.843
(0.742–0.944)
0.857
(0.764–0.950)
0.847
(0.747–0.947)
0.875
(0.781–0.969)
0.863
(0.767–0.960)
Sensitivity 0.846
(0.651–0.956)
(22/26)
0.875
(0.676–0.973)
(21/24)
0.808
(0.606–0.934)
(21/26)
0.750
(0.533–0.902)
(18/24)
0.731
(0.522–0.884)
(19/26)
Specificity 0.799
(0.747–0.845)
(223/279)
0.770
(0.700–0.830)
(134/174)
0.796
(0.744–0.841)
(222/279)
0.902
(0.848–0.942)
(157/174)
0.932
(0.896–0.959)
(260/279)
PPV* 0.427
(0.359–0.498)
(22/78)
0.402
(0.330–0.478)
(21/61)
0.411
(0.341–0.485)
(21/78)
0.575
(0.449–0.692)
(18/35)
0.654
(0.536–0.756)
(19/38)
NPV* 0.967
(0.923–0.986)
(223/227)
0.972
(0.924–0.990)
(134/137)
0.959
(0.914–0.981)
(222/227)
0.953
(0.911–0.976)
(157/163)
0.951
(0.912–0.974)
(260/267)
LR+ 4.22
(3.17–5.61)
3.81
(2.79–5.20)
3.95
(2.93–5.33)
7.68
(4.62–12.75)
10.73
(6.56–17.57)
LR– 0.19
(0.08–0.48)
0.16
(0.06–0.47)
0.24
(0.11–0.53)
0.28
(0.14–0.55)
0.29
(0.15–0.54)
Data presented as % (95% CI) or % (95% CI) (n/N), unless indicated otherwise. *NPV and PPV calculated using assumed prevalence of
15% for preterm pre-eclampsia. AUC, area under receiver–operating characteristics curve; EDTA, ethylenediaminetetraacetic acid; LR–,
negative likelihood ratio; LR+, positive likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
 2018 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2019; 53: 62–67.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
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DISCUSSION
Main findings
This large head-to-head comparison of three commercially
available PlGF-based tests for the prediction of delivery
in women with suspected preterm pre-eclampsia demon-
strates equivalent performance between them and sup-
ports their use as rule-out tests for women presenting
with preterm pre-eclampsia prior to 35weeks’ gestation.
Results between 35 and 37weeks continued to demon-
strate high NPVs of between 0.861 and 0.933, but this
subgroup analysis was limited by smaller numbers.
We compared thresholds that were commercially
recommended and derived from previous literature for
the Elecsys and Alere assays, with an optimally derived
threshold for the DELFIA Xpress PlGF 1-2-3 test. At these
thresholds, tests with higher sensitivities (DELFIA Xpress
PlGF 1-2-3 test and Triage PlGF) had lower specificities,
and similarly that with the highest specificity (Elecsys
immunoassay sFlt-1/PlGF) had the lowest sensitivity, but
the overall test performance appeared to be similar. It has
been suggested previously that high sensitivity is a more
useful attribute in the early detection of pre-eclampsia
than specificity because consideration of benefits, harms
and costs indicates a much greater preference for mini-
mizing false negatives than false positives9. In this regard
all three tests are comparable. Differences were noted in
the lower ranges of detection levels between platforms,
which may reflect measurement of differing isoforms.
Strengths and limitations
Strengths of the study are the use of adjudicated criteria
for classifying pregnancy outcomes, that samples were
analyzed simultaneously on all three platforms under
similar conditions and the use of samples which had not
been exposed to freeze–thaw cycles1,4. The derivation
of a cut-off level of 150 pg/mL for the DELFIA Xpress
PlGF 1-2-3 test focused on obtaining a high sensitivity,
similar to that of the Triage PlGF test, whereas Elecsys
immunoassay sFlt-1/PlGF cut-offs focus on obtaining a
high specificity. As a result, direct comparison of each test
outcome must be interpreted according to for what the
test cut-offs have been optimally derived.
Interpretation
The three PlGF-based tests have similar performance
in predicting delivery in women with suspected preterm
pre-eclampsia. The Triage PlGF results were consistent
with those published elsewhere10. Similarly, the Elecsys
immunoassay sFlt-1/PlGF ratio results were consistent
with those of the PROGNOSIS study, in which it had a
sensitivity of 0.86 (95% CI, 0.73–0.94) and NPV of 0.99
(95% CI, 0.98–1.00) for ruling out pre-eclampsia within
1week7. Benton et al.11 previously conducted a compari-
son of the Triage PlGF assay and the Elecsys sFlt-1/PlGF
ratio in diagnosing pre-eclampsia, and demonstrated that
the Triage test had a greater sensitivity at only a small
reduction in specificity compared with the Elecsys assay.
Stepan et al.10 performed a similar comparison, conclud-
ing that the automated Elecsys immunoassay sFlt-1/PlGF
ratio provided improved diagnostic utility over the Triage
PlGF assay, with higher specificity. The present study pro-
vides an adequately powered head-to-head comparison of
three PlGF-based assays, with a considerably larger num-
ber of cases of preterm pre-eclampsia than used in other
studies that compared two tests10.
Conclusions
The findings of this study support the role of PlGF
as a rule-out test for pre-eclampsia, with NPVs between
0.95 and 0.97. Test results were similar between
the DELFIA Xpress PlGF 1-2-3 test, the Triage PlGF
test and the Elecsys immunoassay sFlt-1/PlGF ratio.
We recommend a threshold of 150 pg/mL for the
DELFIA Xpress PlGF 1-2-3 test to rule out suspected
pre-eclampsia, which gives similar test performance
to that of the other recommended assays. Considering
the significant differences that occur between healthcare
systems, further studies are now needed to compare
implementation of these assays in clinical practice,
including optimal thresholds and associated costs, and to
consider the development of point-of-care testing for use
in a variety of settings.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Figure S1 Receiver–operating characteristics curves for prediction of delivery within 14 days from testing in
women presenting with suspected pre-eclampsia prior to 35weeks’ gestation.
Table S1 Test performance statistics for low PlGF or high sFlt/PlGF ratio in prediction of delivery within
14 days or delivery by 37weeks’ gestation in women presenting < 37weeks’ gestation
Table S2 Test performance statistics for low PlGF or high sFlt/PlGF ratio in prediction of delivery within
14 days secondary to suspected pre-eclampsia or delivery by 37weeks’ gestation, in all women sampled
between 35 and 36+ 6weeks’ gestation
Table S3 Test performance statistics for low PlGF or high sFlt/PlGF ratio in prediction of delivery within
14 days in women with confirmed pre-eclampsia <35weeks’ gestation
Table S4 Comparison of PlGF concentrations in plasma and serum for DELFIA Xpress PlGF 1-2-3 test and
Elecsys immunoassay sFlt-1/PlGF ratio for prediction of delivery within 14 days in women presenting with
suspected pre-eclampsia < 35weeks’ gestation
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